Sign in Subscribe
Chairpersons

HUTCHMED Announces Dr. Weiguo Su's Leave of Absence and Mr. Johnny Cheng as Acting CEO

Strategic Insights

— 2 min read

Dr. Weiguo Su, Chief Executive Officer of HUTCHMED, will be taking a leave of absence due to health reasons, effective immediately. Dr. Su has been a driving force behind the company's success, leading it to build a portfolio of drugs and strategies to deliver additional value. In his absence, Mr. Johnny Cheng, Executive Director and Chief Financial Officer, will take on the role of Acting Chief Executive Officer, in addition to his current responsibilities. The Board of Directors expresses its full support for Dr. Su and wishes him a speedy recovery, and has confidence in Mr. Cheng's capabilities to lead the company during this interim period.

Key Takeaways:

  • Dr. Weiguo Su, Chief Executive Officer of HUTCHMED, will be taking a leave of absence due to health reasons, effective immediately.
  • Mr. Johnny Cheng, Executive Director and Chief Financial Officer, will assume the role of Acting Chief Executive Officer, in addition to his current responsibilities.
  • The Board of Directors has full confidence in Mr. Cheng's capabilities to lead the company during this interim period.
  • Dr. Su has been a driving force behind the company's success, leading it to build a portfolio of drugs and strategies to deliver additional value.
  • The company's research, development, and commercial initiatives will remain on track, according to Dr. Eldar, Chairman and Non-executive Director.
  • Dr. Su has expressed his gratitude to the company and its employees for their support, and has expressed his confidence in Mr. Cheng's leadership.
  • Mr. Cheng has stated that he will endeavor to ensure the company's on-track delivery and has wished Dr. Su a speedy recovery.
  • The company's strategy to successfully build new platforms and capabilities to deliver additional value will remain intact, according to Mr. Cheng.

Statistics:

  • Dr. Su has been an Executive Director of HUTCHMED since 2011 and has been Chief Executive Officer since 2018.
  • Mr. Cheng has been an Executive Director of HUTCHMED since 2011 and has been Chief Financial Officer since 2008.
  • The company has a portfolio of drugs and strategies to deliver additional value, with its first three medicines marketed in China and approved in the US, Europe, and Japan.
  • Mr. Cheng received a Bachelor of Economics, Accounting Major from the University of Adelaide and is an associate of Chartered Accountants Australia and New Zealand.
  • As at the date of the announcement, Mr. Cheng had a personal interest in 2,936,430 ordinary shares of the Company, representing approximately 0.34% of the issued shares.

Sources:

  • HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13)
  • GLOBE NEWSWIRE, August 25, 2025
  • HUTCHMED's website: hutch-med.com
  • FTI Consulting: HUTCHMED@fticonsulting.com
  • Brunswick: HUTCHMED@brunswickgroup.com
  • Cavendish: Geoff Nash / Nigel Birks +44 20 7220 0500

Read more